Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 19 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

74%

14 trials in Phase 3/4

Results Transparency

0 of 18 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

14(73.7%)

Phase 2

4(21.1%)

Phase 1

1(5.3%)

19Total

Phase 3(14)

Phase 2(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT05177939Phase 3Unknown

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

Role: lead

NCT03794310Phase 3Completed

Study of NPF-08 in Patients Who Receive Colonoscopy

Role: lead

NCT02265939Phase 2Completed

Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy

Role: lead

NCT04097574Phase 2Completed

Study of NPO-13 During Colonoscopy

Role: lead

NCT03263910Phase 3Completed

Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

Role: lead

NCT03423771Phase 1Completed

Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers

Role: lead

NCT01845584Phase 2Completed

Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Role: lead

NCT02221271Phase 3Completed

Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome

Role: lead

NCT02250391Phase 3Completed

Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis

Role: lead

NCT01827072Phase 3Completed

Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.

Role: lead

NCT01824251Phase 3Completed

Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Role: lead

NCT01696500Phase 3Completed

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Role: lead

NCT01408550Phase 3Completed

Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids

Role: lead

NCT01411189Phase 3Completed

Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

Role: lead

NCT01411176Phase 3Completed

Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

Role: lead

NCT00742599Phase 3Completed

Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

Role: lead

NCT00740324Phase 3Completed

Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men

Role: lead

NCT00745459Phase 3Completed

Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

Role: lead

NCT00809822Phase 2Completed

Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.

Role: lead

All 19 trials loaded